It is not objectively good news, but Rocket Lab found a defect before risking catastrophic failure on the launchpad.

Rocket Lab Corporation remains a buy despite an expected nearly one-year Neutron rocket delay and increased perceived risk.

Rocket Lab shares have already closed above $100 once this year, and a specific upcoming milestone could force Wall Street to ...

Rocket Lab faces a major setback as its much-awaited Neutron rocket launch is delayed to 2027. I rate RKLB stock as Sell.

Rocket Lab’s updated analyst models show a small trim in fair value, with the price target shifting from about US$105.05 to ...

Rocket Lab's growth story is impressive, but investors still need to separate business momentum from what its stock price ...

The stock has been on an extended slide, and a recent setback further fueled the selling.

Management's schedule for positive adjusted EBITDA hinges on that first launch. Has the sell-off priced in the wait?

Rocket Lab Corp. shares plunged after the company again delayed the debut of its more powerful Neutron rocket, pushing the vehicle’s first flight to 2027.

Rocket Lab has shed a quarter of its value in months, yet a growing chorus of Wall Street analysts sees a path to returns ...

Rocket Lab is keeping us waiting for Neutron.

Rocket Lab faces renewed valuation pressure after its Neutron rocket debut was moved to 2027. A Simply Wall St analysis ...